Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary

키워드

참고문헌 (59)

1. Lee MS, "The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD):report of the Korean Society of Depressive and Bipolar Disorders", Int J Psychiatry Clin Pract, 10, pp.186~194 (2006)
2. 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
3. Seo JS, "The Korean Medication Algorithm for Depressive Disorder : second revision", J Affect Disord, 167, pp.312~321 (2014)
4. Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
5. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
6. Bauer M, "Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines", Int J Psychiatry Clin Pract, 21, pp.166~176 (2017)
7. Cleare A, "Evidence-based guidelines for treating depressive disorders with antidepressants : a revision of the 2008British Association for Psychopharmacology guidelines", J Psychopharmacol, 29, pp.459~525 (2015)
8. Spielmans GI, "Adjunctive atypical antipsychotic treatment for major depressive disorder : a meta-analysis of depression, quality of life, and safety outcomes", PLoS Med, 10, pp.e1001403~ (2013)
9. Schulberg HC, "Treating major depression in primary care practice : an update of the Agency for Health Care Policy and Research Practice Guidelines", Arch Gen Psychiatry, 55, pp.1121~1127 (1998)
10. Williams JW Jr, "A systematic review of newer pharmacotherapies for depression in adults : evidence report summary", Ann Intern Med, 132, pp.743~756 (2000)
11. Fava M, "Background and rationale for the sequenced treatment alternatives to relieve depression(STAR*D)study", Psychiatr Clin North Am, 26, pp.457~494 (2003)
12. Fava M, "Definition and epidemiology of treatment-resistant depression", Psychiatr Clin North Am, 19, pp.179~200 (1996)
13. Nelson JC, "Atypical antipsychotic augmentation in major depressive disorder : a meta-analysis of placebocontrolled randomized trials", Am J Psychiatry, 166, pp.980~991 (2009)
14. Cipriani A, "Comparative efficacy and acceptability of 21antidepressant drugs for the acute treatment of adults with major depressive disorder : a systematic review and network meta-analysis", Lancet, 391, pp.1357~1366 (2018)
15. "Drugs@FDA: FDA-approved drugs"[URL]
16. "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic"[URL]
17. Sheng Min Wang, "Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis", Clinical Psychopharmacology and Neuroscience, 19(2), pp.341~354 (2021), 대한정신약물학회[DOI]
18. Alonso-Pedrero L, "Effects of antidepressant and antipsychotic use on weight gain : a systematic review", Obes Rev, 20, pp.1680~1690 (2019)
19. Pollock BG, "Adverse reactions of antidepressants in elderly patients", J Clin Psychiatry, 60(Suppl 20), pp.4~8 (1999)
20. Barbui C, "Selective serotonin reuptake inhibitors and risk of suicide : a systematic review of observational studies", CMAJ, 180, pp.291~297 (2009)
21. Freeman RA, "Antidepressants’ black-box warning-10 years later", N Engl J Med, 371, pp.1666~1668 (2014)
22. Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders : major depression summary", Bipolar Disord, 22, pp.788~804 (2020)
23. Norman TR, "Agomelatine for depression: expanding the horizons?", Expert Opin Pharmacother, 20, pp.647~656 (2019)
24. Sohn CH, "Treatment of seasonal affective disorder : unipolar versus bipolar differences", Curr Psychiatry Rep, 6, pp.478~485 (2004)
25. Galima SV, "Seasonal affective disorder : common questions and answers", Am Fam Physician, 102, pp.668~672 (2020)
26. Changsu Han, "The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study", Clinical Psychopharmacology and Neuroscience, 17(4), pp.495~502 (2019), 대한정신약물학회[DOI]
27. Jong Hyun Jeong, "Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 17(2), pp.155~169 (2019), 대한정신약물학회[DOI]
28. Young-Min Park, "The Mixed-Features Specifier of Major Depressive Disorder in DSM-5: Is It Practical?", PSYCHIATRY INVESTIGATION, 15(11), pp.1009~1010 (2018), 대한신경정신의학회[DOI]
29. Koukopoulos A, "Mixed features of depression : why DSM-5 is wrong(and so was DSM-IV)", Br J Psychiatry, 203, pp.3~5 (2013)
30. Ng CH, "Definition of treatment-resistant depression-Asia Pacific perspectives", J Affect Disord, 245, pp.626~636 (2019)
31. Baweja R, "Disruptive mood dysregulation disorder : current insights", Neuropsychiatr Dis Treat, 12, pp.2115~2124 (2016)
32. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
33. Yoo HK, "Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders", Eur Child Adolesc Psychiatry, 20, pp.127~135 (2011)
34. Tomson T, "Dose-dependent risk of malformations with antiepileptic drugs : an analysis of data from the EURAP epilepsy and pregnancy registry", Lancet Neurol, 10, pp.609~617 (2011)
35. Meador K, "Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts", Epilepsy Res, 81, pp.1~13 (2008)
36. MacQueen GM, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly", Can J Psychiatry, 61, pp.588~603 (2016)
37. Ghaemi SN, ""Cade’s disease"and beyond : misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder", Can J Psychiatry, 47, pp.125~134 (2002)
38. Hetrick SE, "Newer generation antidepressants for depressive disorders in children and adolescents", Cochrane Database Syst Rev, 11, pp.CD004851~ (2012)
39. Wagner KD, "A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression", J Am Acad Child Adolesc Psychiatry, 45, pp.280~288 (2006)
40. Cipriani A, "Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents : a network meta-analysis", Lancet, 388, pp.881~890 (2016)
41. Findling RL, "Escitalopram in the treatment of adolescent depression : a randomized, double-blind, placebocontrolled extension trial", J Child Adolesc Psychopharmacol, 23, pp.468~480 (2013)
42. Stahl SM, "Stahl’s essential psychopharmacology: neuroscientific basis and practical application", pp.48~51 (2013), Cambridge University Press
43. "Last year, 450,000women suffered from depression… twice that of men" (2018)[URL]
44. Young-Eun Jung, "Validation of the Korean Version of the Depression in Old Age Scale and Comparison with Other Depression Screening Questionnaires Used in Elderly Patients in Medical Settings", Clinical Psychopharmacology and Neuroscience, 17(3), pp.369~376 (2019), 대한정신약물학회[DOI]
45. Steffens DC, "Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients : a pooled subpopulation analysis", Int J Geriatr Psychiatry, 26, pp.564~572 (2011)
46. Lenze EJ, "Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life : a randomised, double-blind, placebo-controlled trial", Lancet, 386, pp.2404~2412 (2015)
47. Cakir S, "Atypical antipsychotics as add-on treatment in late-life depression", Clin Interv Aging, 11, pp.1193~1198 (2016)
48. Mulsant BH, "A systematic approach to pharmacotherapy for geriatric major depression", Clin Geriatr Med, 30, pp.517~534 (2014)
49. "National guidelines for seniors’ mental health-the assessment and treatment of depression" (2006)[URL]
50. Sachs GS, "The expert consensus guideline series : medication treatment of bipolar disorder 2000", Postgrad Med, (Spec No), pp.1~104 (2000)
51. Hofmeister S, "Premenstrual syndrome and premenstrual dysphoric disorder", Am Fam Physician, 94, pp.236~240 (2016)
52. Lanza di Scalea T, "Premenstrual dysphoric disorder", Med Clin North Am, 103, pp.613~628 (2019)
53. Sujita Kumar Kar, "Predictors of Response to Repetitive Transcranial Magnetic Stimulation in Depression: A Review of Recent Updates", Clinical Psychopharmacology and Neuroscience, 17(1), pp.25~33 (2019), 대한정신약물학회[DOI]
54. Po-Han Chou, "Personalization of Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder According to the Existing Psychiatric Comorbidity", Clinical Psychopharmacology and Neuroscience, 19(2), pp.190~205 (2021), 대한정신약물학회[DOI]
55. Milev RV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder:section 4. Neurostimulation treatments", Can J Psychiatry, 61, pp.561~575 (2016)
56. Rigonatti SP, "Transcranial direct stimulation and fluoxetine for the treatment of depression", Eur Psychiatry, 23, pp.74~76 (2008)
57. Brunoni AR, "The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial", JAMA Psychiatry, 70, pp.383~391 (2013)
58. Oliveira JF, "Acute working memory improvement after tDCS in antidepressant-free patients with major depressive disorder", Neurosci Lett, 537, pp.60~64 (2013)
59. Brunoni AR, "Enhancement of affective processing induced by bifrontal transcranial direct current stimulation in patients with major depression", Neuromodulation, 17, pp.138~142 (2014)

관련 논문AI추천